menu search

helocyte announces $3.22 million grant from the national cancer institute for triplex phase 2 clinical trial program

Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-spec...

June 15, 2023, 12:00 pm


Search within

Pages Search Results: